Additionally, McAdow et al. examined the pathogenic mechanisms associated with myopathies linked to TPM2 variants. Their research utilized Drosophila and zebrafish models to demonstrate that specific pathogenic variants disrupt muscle development and function, indicating a critical role for TPM2 in myogenesis (ref: McAdow doi.org/10.1172/jci.insight.152466/). This aligns with the findings of Ko et al., who compared the efficacy of intradermal versus intramuscular hepatitis B vaccination in patients with inflammatory bowel disease, revealing that intradermal vaccination offers superior immunogenicity (ref: Ko doi.org/10.1111/apt.16970/). Together, these studies highlight the multifaceted nature of muscle repair mechanisms and the potential for targeted interventions to enhance muscle regeneration in various pathological contexts.

Moreover, Wang et al. utilized CRISPR/Cas9 technology to modify duplications causing DMD, demonstrating the potential of genome editing in correcting genetic defects (ref: Wang doi.org/10.1038/s41434-022-00336-3/). This innovative approach could pave the way for future therapeutic strategies targeting genetic mutations in myopathies. The interplay between genetic factors and therapeutic interventions is further illustrated by the study of Madkour et al., who investigated the renoprotective effects of lactoferrin in acute kidney injury, highlighting the importance of metabolic pathways in muscle health (ref: Madkour doi.org/10.1016/j.lfs.2022.120646/). Collectively, these studies provide a comprehensive overview of the genetic and molecular mechanisms underlying myopathies, emphasizing the need for personalized approaches in treatment.

In addition, Zarrouki et al. explored the behavioral deficits associated with Duchenne muscular dystrophy, demonstrating that restoring brain dystrophin can alleviate cognitive impairments in mdx mice (ref: Zarrouki doi.org/10.1002/ana.26409/). This highlights the interconnectedness of muscular and neurological aspects of myopathies. Forouhan et al. examined the role of androgens in maintaining skeletal muscle homeostasis, revealing that androgen receptor signaling is crucial for muscle mass regulation (ref: Forouhan doi.org/10.1007/s00401-022-02428-1/). Collectively, these studies underscore the necessity of integrating clinical and epidemiological data to inform treatment approaches and improve patient outcomes in myopathies.

Moreover, Zarrouki et al. explored the use of exon skipping to restore brain dystrophin in mdx mice, which could alleviate cognitive deficits associated with Duchenne muscular dystrophy (ref: Zarrouki doi.org/10.1002/ana.26409/). This innovative genetic approach exemplifies the potential of gene therapy in addressing the underlying causes of myopathies. Wang et al. also employed CRISPR/Cas9 technology to modify genetic duplications in DMD, showcasing the promise of genome editing in developing personalized therapies (ref: Wang doi.org/10.1038/s41434-022-00336-3/). These studies collectively highlight the importance of advancing therapeutic interventions through innovative methodologies and personalized approaches to improve outcomes for patients with myopathies.

Additionally, Verstappen et al. examined the differences in joint inflammation patterns between ACPA-positive and ACPA-negative rheumatoid arthritis patients, providing insights into the inflammatory processes underlying autoimmune conditions (ref: Verstappen doi.org/10.1093/rheumatology/). This research emphasizes the need for tailored therapeutic strategies based on serological profiles. Furthermore, Minerbi et al. explored the gut microbiome's role in fibromyalgia, revealing alterations in bile acid profiles associated with symptom severity, which may inform future therapeutic approaches targeting the gut-brain axis (ref: Minerbi doi.org/10.1097/j.pain.0000000000002694/). Collectively, these studies underscore the complexity of inflammatory and autoimmune myopathies and the necessity for comprehensive, individualized treatment strategies.

Moreover, Uhlmann et al. surveyed dietitians in Switzerland regarding the assessment and monitoring of muscle parameters during nutritional care, revealing gaps in practice that could impact the management of malnutrition and sarcopenia (ref: Uhlmann doi.org/10.3390/nu14091741/). These findings emphasize the importance of integrating muscle health assessments into nutritional strategies. Additionally, Ko et al. compared intradermal and intramuscular hepatitis B vaccinations in patients with inflammatory bowel disease, finding that intradermal vaccination offers superior seroprotection, which could have implications for managing muscle health in this population (ref: Ko doi.org/10.1111/apt.16970/). Together, these studies highlight the multifaceted nature of muscle atrophy and metabolic disorders, emphasizing the need for comprehensive approaches to prevention and treatment.

Furthermore, Sabbatini et al. investigated genetic modifiers of upper limb function in DMD, emphasizing the role of genetic factors in influencing neurological outcomes in muscular dystrophies (ref: Sabbatini doi.org/10.1007/s00415-022-11133-8/). Madkour et al. examined the renoprotective effects of lactoferrin in acute kidney injury, suggesting that metabolic health is intricately linked to neuromuscular function (ref: Madkour doi.org/10.1016/j.lfs.2022.120646/). Collectively, these studies highlight the importance of understanding neuro-muscular interactions and their implications for developing effective therapeutic strategies for myopathies.